ABSTRACT
INTRODUCTION
Cervical pregnancy (CP) is a type of ectopic pregnancy in which the trophoblast develops in the cervical glands and the fibrous cervical wall 1 . It is rare, with an estimated incidence of approximately 1 in 8628-10 000 deliveries 2, 3 , and 1 in 455 (0.2%) ectopic pregnancies 4 . CP is considered to be associated with in-vitro fertilization (IVF) or a history of prior curettage 5 . In an analysis of 3145 transfer cycles after IVF, subsequent CP was diagnosed in one patient from a total of 825 (0.1%) pregnancies and 27 (3.7%) ectopic pregnancies 5 . Because the most common symptom is painless vaginal bleeding, which may lead to massive hemorrhage, it is necessary to identify and manage CP at an early stage 1 . Various medical and surgical treatments for CP have been reported, but there are still no standard treatment protocols. Methotrexate (MTX) is generally the first-line method of choice for clinically stable women and has been administered systemically or injected locally in individual cases and series 1 . We preserved successfully an intrauterine gestation in a patient with a simultaneous CP through the use of an ultrasound-guided local MTX injection into the cervical gestation 6 . Since then, we have been applying a single local MTX injection as the initial treatment for both CPs and Cesarean scar pregnancies 7 . Previous studies have suggested that local MTX injection may be effective as an initial treatment for CP; however, in most cases, concomitant procedures or surgical interventions were used in combination with the injection [8] [9] [10] [11] [12] [13] . The efficacy of a single local MTX injection without concomitant procedures for treating CP has not been reported, and the prognosis of these patients is unclear. In this study, we examined the efficacy of a single local MTX injection given under transvaginal ultrasound guidance to treat CP, and assessed post-treatment fertility.
METHODS
We reviewed retrospectively all CP patients treated at Kumamoto University Hospital between May 2007 and October 2015. The diagnosis was based on the patient's medical history, a clinical examination, serum human chorionic gonadotropin (hCG) levels, transvaginal ultrasonography and, in some cases, magnetic resonance imaging (MRI). The serum levels of intact hCG were measured using automated electrochemiluminescence immunoassays (TOSOH, Tokyo, Japan). Ultrasound examinations were performed using a 5-7.5-MHz mechanical sector probe (Mochida, Tokyo, Japan), with the following criteria used to establish the diagnosis: 1) a gestational sac in the cervical glands or trophoblastic invasion into the cervical glands if an entire gestational sac was not located in the cervix; 2) a yolk sac, a fetus or cardiac activity identified in the gestational sac; 3) presence of blood flowing around the gestational sac, detected by Doppler studies; 4) absence of a sliding sign, which would indicate a miscarriage. In patients who had had a previous Cesarean delivery, we excluded a diagnosis of Cesarean scar pregnancy by reference to the previously reported criteria for this diagnosis 7 . MRI was performed as an adjunct to ultrasonography when the implantation site was obscure or when the clinical course indicated it 14 . After diagnosis, a patient's baseline blood count and liver and kidney status were assessed, followed by treatment with ultrasound-guided transvaginal local injection of 50 mg MTX dissolved in 2 mL distilled water. This was achieved using a 21-gauge percutaneous transhepatic cholangiography needle (Hakko, Tokyo, Japan) attached to a transvaginal probe. The needle was introduced, under transvaginal ultrasound guidance, into the gestational sac via the vaginal fornix. When the amniotic sac was large enough to allow aspiration, amniotic fluid was first aspirated. The 50 mg MTX was then injected into the gestational sac and the stroma of the uterine cervix surrounding it. In cases in which the flow around the gestational sac could be visualized by color Doppler, MTX was administered into the region of flow. The procedure was performed in an operating room with the patient under general anesthesia to prevent her movement and to prepare for potentially serious bleeding. We used the same procedure on all clinically stable CP patients, both those with and those without fetal cardiac activity and regardless of initial hCG level.
The day of treatment was defined as day 0, and the serum hCG levels were monitored until they became negative. The ratio of the serum hCG level to that on day 0 was evaluated, by defining the baseline level on day 0 as 100% and calculating the percentage relative to this, every 1-3 days during the first 2 weeks after the treatment. An additional local MTX injection was administered when the serum hCG levels on day 5, or those on the first working day after that if day 5 was during the weekend, exceeded the previous value. The gestational sac was also observed by ultrasonography until the sac resolved completely. During the follow-up period, the mean time required for hCG normalization, the duration until menses resumed, the treatment success rate and the subsequent parturition rate in patients desiring pregnancy were analyzed.
All CP patients were numbered (Patients 1-15) in order of admission. Descriptive statistics are presented as median (range), percentage or mean (95% CI). The study was approved by Kumamoto University Hospital Review Board, and all patients gave their written informed consent to participate in the study.
RESULTS

Clinical characteristics
Fifteen patients were diagnosed with CP at our institution during the study period. Their characteristics are summarized in Table 1 . All patients were referred to our hospital by their primary physicians. Their median age at the time of diagnosis was 32 (range, 23-42) years. Nine (60.0%) patients were nulliparous and two (13.3%) had had a Cesarean delivery previously. Eight (53.3%) patients had a history of uterine curettage. Twelve pregnancies were conceived spontaneously, and three had been conceived through IVF-embryo transfer (Patients 12, 13 and 15). One patient had a septate uterus, and one patient had a myoma in the posterior wall of the uterine cervix (Patients 5 and 12, respectively). Twelve (80.0%) patients presented with vaginal bleeding. Fetal cardiac activity was present in six (40.0%) patients at presentation. MRI was performed as an adjunct to ultrasonography in three patients because the latter showed findings uncharacteristic of CP (Patients 5, 9 and 14). After the diagnosis of CP, all 15 patients were treated initially with a transvaginal ultrasound-guided local MTX injection. The median estimated gestational age at the time of the injection was 6 + 2 (range, 5 + 2 to 11 + 0) days. The median serum hCG level prior to initial treatment was 11 565 (range, 2323-100 578 mIU/mL).
Pattern of hCG level resolution and need for additional treatment
The pattern of change in the serum hCG ratio in all 15 CP patients during the first 2 weeks after MTX injection is presented in Figure 1 . After the local MTX injection, hCG levels increased above the levels observed on day 0 in nine patients (Patients 2, 3, 4, 6, 10, 11, 13, 14 and 15). Of these patients, the hCG levels on day 5 exceeded the previous value in three patients; therefore, an additional local MTX injection into the uterine cervix in the presence of color flow on Doppler imaging was required: on day 5 in Patient 3 and on day 7 in Patients 4 and 11. The hCG levels in all patients were reduced by more than 50% within 2 weeks.
Uterine artery embolization after local MTX injection
A 35-year-old Japanese woman (gravida 1, para 0), who had undergone two uterine curettage procedures after a diagnosis of hydatidiform mole at the age of 33 years, was referred to Kumamoto University Hospital because of suspicion of a CP at 8 + 1 weeks of pregnancy (Patient 9). The patient's serum hCG level was 100 578 mIU/mL. Transvaginal ultrasonography revealed that there was a gestational sac with a yolk sac without a fetus in the uterine cavity; however, the chorion frondosum with blood flow had invaded into the stroma of the uterine cervix (Figure 2a) . MRI showed an enlarged lesion with dilated vessels in the uterine cervix that was connected to the gestational sac in the uterine cavity (Figure 2b ). These findings led to a diagnosis of CP. On the same day as the examination, 50 mg MTX was injected into the stroma of the uterine cervix under ultrasonographic guidance, and the serum hCG levels were observed to decrease continuously thereafter. However, the patient's vaginal bleeding continued, and she started to complain of abdominal pain. Her cervical mass, showing color flow on Doppler interrogation, started to enlarge about 1 month after the MTX injection and continued to enlarge gradually on successive ultrasound examinations, although the hCG levels had declined to 23.9 mIU/mL on day 54. MRI on day 55 showed an irregular lesion of 6 × 6 × 7.5 cm in the cervix, with high intensity on P1  P2  P3  P4  P5  P6  P7  P8  P9  P10  P11  P12  P13  P14  P15 Serum hCG ratio (%)
Time since treatment (days) Figure 1 Change in human chorionic gonadotropin (hCG) ratio from hCG level on day 0 during first 2 weeks after local methotrexate (MTX) injection for cervical pregnancy. An additional local MTX injection was required on day 5 in Patient (P) 3 and on day 7 in Patients 4 and 11 because their hCG level on day 5 exceeded that of previous value. hCG levels in all patients were reduced by more than 50% within 2 weeks.
T1-weighted imaging and low intensity on T2-weighted imaging (Figure 2c ). Dynamic contrast-enhanced MRI revealed shadows of blood vessels (Figure 2d ) with enhancement of an area in the enlarging mass being observed, and three-dimensional aortography showed bilateral dilated peripheral uterine arteries ( Figure 2e ). As a result of these observations, as well as continued vaginal bleeding, the patient underwent uterine artery embolization (UAE) on day 56. The vaginal bleeding subsequently stopped, and the treated sac was expelled spontaneously on day 94 (Figure 2f ). The patient later conceived spontaneously and had an uneventful pregnancy, delivering vaginally a 3150-g newborn at 39 weeks of gestation, 16 months after the local MTX injection.
Outcome after treatment and following parturition
Of the 15 CP patients, 11 were treated successfully by a single local MTX injection, while three required an additional MTX injection due to a poor decline in hCG levels and one required UAE due to persistent vaginal bleeding and enlargement of the treated sac, with blood flow. There was little blood loss during local MTX injection in any patient. No patient required systemic MTX injection, curettage, surgical treatment or a blood transfusion. No adverse effects related to the MTX treatment were observed. The outcomes of the patients are summarized in Table 1 . The mean time required for hCG normalization was 43.8 (95% CI, 33.3-54.3) days, and menstruation resumed after a mean of 68.4 (95% CI, 51.9-84.9) days. The median observation period after MTX treatment was 63 (range, 2-104) months. Twelve patients were followed up for more than 6 months after treatment, 10 of whom desired subsequent pregnancies. Seven of the 10 patients had uneventful pregnancy during the follow-up period (Table 2) . Of these seven patients, one (Patient 12) underwent an IVF procedure after resection of a cervical myoma. All seven patients delivered at term, at a mean of 27.3 (95% CI, 8.8-45.6) months after the treatment. Of the remaining three patients who desired subsequent pregnancy, one patient (Patient 1) miscarried spontaneously at 8 weeks of gestation, one (Patient 4) was treated by laparoscopic surgery after diagnosis of a tubal pregnancy and one (Patient 5) did not conceive. The rate of parturition in women desiring to conceive after CP treatment was therefore 70%.
DISCUSSION
Our results indicate that a single ultrasound-guided local MTX injection is effective for the treatment of CP, without need for concomitant procedures or surgical intervention. In addition, this conservative technique preserves fertility and enables the possibility of subsequent uneventful pregnancy. MTX has been administered both systemically (intramuscular injection) and locally for the treatment of CP. Systemic administration of MTX alone does not appear to be effective for CP patients 15 ; apparently it is more effective if local injections of potassium chloride (KCl) or UAE are also applied [16] [17] [18] (Table 3) . In 1994, Timor-Tritsch et al. 8 first reported that single ultrasound-guided transvaginal local injection of MTX was effective for five CP patients, only one of whom subsequently required curettage due to a poor decline Only first author of each study is given. D&C, dilation and curettage; KCl, potassium chloride; UAE, uterine artery embolization. in hCG levels. Since then, there have been a further five publications 9-13 , each reporting five or more cases of patients treated initially with local MTX injection, although concomitant treatments were used in all of these reports (Table 4) . MTX was injected transabdominally in one study 10 ; however, the needle perforated the bladder in three patients. Therefore, transvaginal injection of MTX under ultrasound guidance appears to be safer for the treatment of CP patients. There is currently no consensus regarding the appropriate dose of MTX for local injection to treat CP. In previous studies it has been used in total doses of 25-70 mg or 1 mg/kg. In the present study, MTX was administered at a fixed total dose of 50 mg, similar to that used in other studies in which single local MTX injections were effective for patients with Cesarean scar pregnancy 7, 19 . No adverse effect related to MTX therapy was observed in any of our patients.
The need, alongside local MTX injection, for a concomitant procedure, such as cervical curettage, systemic MTX administration or local KCl injection, remains controversial. Routine cervical curettage seems to be associated with the possibility of cervical bleeding. Two articles reported on local KCl injection concomitant with local MTX injection if fetal cardiac activity was present 12, 13 . However, the fetal heart beats in all six of our CP patients who initially showed a heart beat disappeared after a single local MTX injection: in our study these patients could be treated uneventfully with just a single local MTX injection. Another study also reported prompt arrest of fetal heart beats following a single local MTX injection without KCl injection in five patients 8 . Further studies are necessary to verify the need for concomitant local KCl injection.
The methods used to evaluate the effects of local MTX injection have likewise not been unified. In four previous studies 8, [11] [12] [13] , additional treatments, such as cervical curettage or systemic MTX administration, were required for CP patients whose hCG levels did not decline smoothly; however, the indications for and the timing of the additional treatment differed in each study. We previously reported that the hCG concentration tended to increase within 6 days after a local MTX injection for patients with Cesarean scar pregnancy 7 . A similar phenomenon was observed in patients with ectopic pregnancy treated with a single intramuscular MTX injection and in patients with Cesarean scar pregnancy treated with intramuscular or local MTX injection 20 -22 . In the present study, the hCG levels increased temporarily above the levels observed on day 0 after local MTX injection in five of the 11 patients who did not require additional treatment, suggesting that this characteristic pattern of change in the serum hCG concentration may not necessarily reflect a poor outcome. Our results suggest that patients whose hCG level on day 5 does not exceed that on day 0 can be observed without any additional intervention following a single local MTX injection. This finding may serve as a useful reference for clinical practice.
It should be noted, however, that a single local MTX injection is apparently of limited effectiveness in some CP patients. Previous studies have reported the necessity for cervical tamponade in CP patients with postoperative cervical bleeding 11, 12 . One patient in our present study, whose serum hCG level was 100 578 mIU/mL, required UAE for postoperative vaginal bleeding. It will be necessary to establish standard protocols for this treatment strategy.
As CP is most likely to be diagnosed in women who are undergoing fertility treatment, the preservation of fertility after CP treatment is particularly important. Of the 61 reported CP patients treated initially with systemic MTX administration, six required hysterectomy (Table 3 ). In contrast, of the 86 reported CP patients, including our 15 patients, treated initially with local MTX injection, none required hysterectomy, and more than 20 subsequently had an uneventful parturition (Table 4) . Local MTX injection may be considered as the first-line treatment for CP patients who desire future fertility.
Limitations of our study include the small study population, the lack of a control group and its retrospective design. Accordingly, further studies are necessary to establish the efficacy of this therapy.
In conclusion, a single ultrasound-guided local MTX injection is apparently effective for the treatment of CP, without a need for concomitant procedures or surgical intervention, although it will be necessary to establish the indications and protocols for this therapy. Furthermore, this conservative technique both preserves fertility and allows for the possibility of subsequent uneventful pregnancy.
